Results 161 to 170 of about 74,688 (254)

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial [PDF]

, 2020
Darren R. Feldman, Yasser Ged, Chung‐Han Lee, Andrea Knežević, Ana M. Molina, Ying‐Bei Chen, Joshua Chaim, Devyn Taylor Coskey, Samuel Murray, Satish K. Tickoo, Victor E. Reuter, Sujata Patil, Han Xiao, Jahan Aghalar, Arlyn Apollo, Maria I. Carlo, Robert J. Motzer, Martin H. Voss   +17 more
openalex   +1 more source

Treatment of Melanoma Cells with Chloroquine and Everolimus Activates the Apoptosis Process and Alters Lipid Redistribution [PDF]

Dorota Ciołczyk-Wierzbicka, Marta Zarzycka, Wojciech Placha, Grzegorz Zemanek, Karol Wierzbicki   +4 more
openalex   +1 more source

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial [PDF]

, 2014
Giovanni Grignani, Emanuela Palmerini, Virginia Ferraresi, Lorenzo D’Ambrosio, Rossella Bertulli, Sebastian Dorin Asaftei, Angela Tamburini, Ymera Pignochino, Dario Sangiolo, Emanuela Marchesi, Federica Capozzi, R. Biagini, Marco Gambarotti, Franca Fagioli, Paolo G. Casali, Piero Picci, Stefano Ferrari, Massimo Aglietta   +17 more
openalex   +1 more source

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial [PDF]

, 2017
Matthew H. Kulke, Philippe Ruszniewski, Eric Van Cutsem, Catherine Lombard‐Bohas, Juan W. Valle, Wouter W. de Herder, Marianne Pavel, Evgeny Degtyarev, Jan C. Brase, Lida Bubuteishvili‐Pacaud, Maurizio Voi, Ramón Salazar, Ivan Borbath, Nicola Fazio, Denis Smith, Jaume Capdevila, Rachel P. Riechelmann, Jin‐Guang Yao   +17 more
openalex   +1 more source

Everolimus in infants with tuberous sclerosis complex–related West syndrome: First results from a single‐center prospective observational study [PDF]

, 2018
Sharon Samueli, Anastasia Dressler, Gudrun Gröppel, Theresa O. Scholl, Martha Feucht   +4 more
openalex   +1 more source

Comparison of long-term clinical outcomes among zotarolimus-, everolimus-, and biolimus-eluting stents in acute myocardial infarction patients with renal impairment

, 2021
Seok Oh, Dae Young Hyun, Kyung Hoon Cho, Ju Han Kim, Myung Ho Jeong   +4 more
openalex   +2 more sources

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors. [PDF]

Breast Cancer Res
Dutheil J, Pereira V, Boisson C, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Viot J, Meynard G, Goujon M, Dalens L, Dubourd C, Marchi S, Meneveau N, Vernerey D, Adotévi O, Meurisse A, Curtit E.   +18 more
europepmc   +1 more source

Supplementary Figure 3 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

, 2023
Filip Jankú, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne M. Velez-Bravo, Tamara G. Barnes, Fredrick B. Hagemeister, Gerald S. Falchook, Daniel D. Karp, Jennifer J. Wheler, Sarina A. Piha‐Paul, Ignacio Garrido‐Laguna, Elizabeth J. Shpall, Luis Fayad, Sattva S. Neelapu, Funda Meric‐Bernstam, Razelle Kurzrock, Michelle A. Fanale   +21 more
openalex   +1 more source

Renal Function Outcomes in Tuberous Sclerosis Complex Patients Receiving Everolimus for Renal Angiomyolipoma. [PDF]

Eur Urol Open Sci
Liao Z, Wang W, Zhao Y, Liu Y, Qiu D, Zhang Y.   +5 more
europepmc   +1 more source